Abstract:Morbidity and mortality caused by invasive Aspergillus infections are increasing. This is because of the higher number of patients with malignancies treated with intensive immunosuppressive therapy regimens as well as their improved survival from formerly fatal bacterial infections, and the rising number of patients undergoing allogeneic haematopoietic stem cell or organ transplantation. Early initiation of effective systemic antifungal treatment is essential for a successful clinical outcome in these patients; however, clinical clues for diagnosis are sparse and early microbiological proof of invasive aspergillosis (IA) is rare. Clinical diagnosis is based on pulmonary CT scan findings and non-culture based diagnostic techniques such as galactomannan or DNA detection in blood or bronchoalveolar lavage samples. Most promising outcomes can be expected in patients at high risk for aspergillosis in whom antifungal treatment has been started pre-emptively, backed up by laboratory and imaging findings. The gold standard of systemic antifungal treatment is voriconazole, which has been proven to be significantly superior to conventional amphotericin B and has led to a profound improvement of survival rates in patients with cerebral aspergillosis. Liposomal amphotericin B at standard dosages appears to be a suitable alternative for primary treatment, while caspofungin, amphotericin B lipid complex or posaconazole have shown partial or complete response in patients who had been refractory to or intolerant of primary antifungal therapy. Combination therapy with two antifungal compounds may be a promising future strategy for first-line treatment. Lung resection helps to prevent fatal haemorrhage in single patients with pulmonary lesions located in close proximity to larger blood vessels, but is primarily considered for reducing the risk of relapse during subsequent periods of severe immunosuppression. Strict reverse isolation appears to reduce the incidence of aspergillosis in allogeneic stem cell transplant recipients and patients with acute myeloid leukaemia undergoing aggressive anticancer therapy. Well designed, prospective randomised studies on infection control measures effective to prevent aspergillosis are lacking. Prophylactic systemic antifungal treatment with posaconazole significantly improves survival and reduces IA in acute myeloid leukaemia patients and reduces aspergillosis incidence rates in patients with intermediate-to-severe graft-versus-host reaction emerging after allogeneic haematopoietic stem cell transplantation. Voriconazole prophylaxis may be suitable for prevention of IA as well; however, the results of large clinical trials are still awaited.

Invasive Pulmonary Aspergillosis Due to Emericella Nidulans Var. Echinulata, Successfully Cured by Voriconazole and Micafungin

Pulmonary aspergillosis and cryptococcosis coexist in a patient with rheumatoid arthritis and tuberculosis

The Diagnosis and Surgical Treatment for 56 Cases with Pulmonary and Pleural Aspergillosis

Successful treatment of Candida tropicalis osteomyelitis with Micafungin in a leukemia patient

Clinical Analysis on Ninty-Six Cases of Secondary Aspergillosis in COPD Patients

[Chronic Necrotizing Pulmonary Aspergillosis: Diagnosis and Treatment].

Invasive pulmonary aspergillosis in autoimmune bullous diseases patients:three cases report

An albino strain of Aspergillus fumigatus causes pulmonary aspergilloma in an individual with normal immune ;system

The intravenous infusion of amphotericin B combined with aerosol inhalation for pulmonary aspergillosis:1 case report

A Case of Pulmonary Histoplasmosis Treated with Voriconazole

Successful treatment of mixed pulmonary Aspergillus and Mucor infection using intrabronchial amphotericin B infusion: a case report and literature review

Successful treatment of Aspergillus mural endocarditis in malignant lymphoma using a combined antifungal and surgical approach: a case report

Emergence of W272C Substitution in Hmg1 in a Triazole-Resistant Isolate of Aspergillus Fumigatus from a Chinese Patient with Chronic Cavitary Pulmonary Aspergillosis.

Successful treatment of Purpureocillium lilacinum pulmonary infection with isavuconazole: A case report

Progress in the Diagnosis and Treatment of Pulmonary Aspergillosis

Pulmonary coinfection by Pneumocystis jirovecii and Aspergillus terreus in an ITP patient after corticosteroid therapy: A case report

Case Reports. Invasive Pulmonary Aspergillosis in Non‐neutropenic Patients Treated with Liposomal Amphotericin B

Efficacy of the Combination of Voriconazole and Caspofungin in Experimental Pulmonary Aspergillosis by Different Aspergillus Species

An immunocompetent lady with invasive aspergillosis presenting as disseminated lesions: a case report

Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients

Clinical and Microbiological Characterization of Invasive Pulmonary Aspergillosis Caused by Aspergillus lentulus in China